Glaucoma

A meditation on the effects of putting off doctors' orders.

Austin Lifferth, OD, FAAO, shares highlights from his AAOpt 2022 presentations, including a triad approach to evaluating the optic nerve in glaucoma, and recentering glaucoma care with these 5 GlaucoMantras.

Researchers reported that the preclinical detectable phase for OAG is about 10 years.

Justin Schweitzer, OD, gives a brief overview of his EyeCon 2022 presentations, reflecting on pipeline advancements made in optometry in 2022.

The glaucoma field is on the move with significant innovations in a number of treatment areas. Experts discussed the various technologies at the Optometry Times 2022 EyeCon meeting in Marco Island, Florida.

As the first and only preservative-free formulation of latanoprost, IYUZEH 0.005% is approved to reduce IOP in patients with open-angle glaucoma or ocular hypertension.

Glaucoma therapy isn't as cookie-cutter as it seems on the surface.

It was reported that the more individuals smoke, the faster the retinal nerve fiber layer (RNFL) becomes thinner.

Optometrists must identify and mitigate complications for this patient base.

Several risk factors beyond intraocular pressure contribute to open-angle glaucoma.

A recent report shows that 61 drugs were associated with the development of acute angle-closure (AAC) glaucoma.

Potential for treatment strategy to prevent blindness from glaucoma.

Recent patient situation stresses needs for peer-to-peer discourse.

As technology improves, less-invasive treatments save patients time and money.

Mitch Ibach, OD, FAAO, shares highlights from his VEW 2022 presentation, "Visual fields, a virtual reality."

Melissa Barnett, OD, from the University of California, Davis Eye Center, Sacramento and Davis, CA, described new strategies, technologies, and drug classes to treat chronic conditions that include myopia, Demodex infestation, meibomian gland dysfunction, glaucoma drug delivery, advancements in corneal and cataract surgeries, and presbyopia

Optometrists are seeing recent advances in topical therapies that entered the market following decades of reliance of traditional single-agent drops. An implantable device that facilitates the slow release of drug is changing the landscape in glaucoma therapy.

Justin Schweitzer, OD, FAAO, reports that glaucoma therapy is quickly moving to more innovative and targeted ways to treat glaucoma and lower the patient treatment burden.

Michael Chaglasian, OD, Illinois College of Optometry, Chicago, and Eric Schmidt, OD, Omni Eye Specialists, Wilmington, NC, share guidelines for ODs on diagnosing glaucoma during the 2022 Vision Expo West in Las Vegas.

Jessica Steen, OD, FAAO, shares highlights from her VEW 2022 presentation, "Ophthalmic therapeutics update."

Leo P. Semes, OD, FAAO, discusses his presentation on, "When glaucoma isn't glaucoma," during the South Carolina Optometric Physicians Association's annual meeting.

Glaucoma search study finds online medical resources lack readability.

A 35-year-old woman presents with ptosis of the right eyelid 4 days after undergoing injection of botulinum toxin type A.

A growing number of less complex and invasive treatments are offering ODs more options for patient care.

Thomas A. Wong, OD, FNAP, and his co-authors Elise Regina, OD, and Kelly Armstrong, OD, discuss corneal hysteresis: part four.